Study used blood test to identify distinct molecular signatures of disease; paves the way to precision medicine for cystic fibrosis
Researchers at Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, and colleagues, used a blood test and microarray technology to identify distinct molecular signatures in children with cystic fibrosis. These patterns of gene expression ultimately could help predict disease severity and treatment response, and lead to therapies tailored to each patient’s precise biology. Findings were published in Physiological Genomics.
“Our findings pave the way to precision medicine for cystic fibrosis patients, eventually helping us match treatment to each patient’s unique genomic pattern of disease,” says lead author Hara Levy, MD, MMSc, from Manne Research Institute at Lurie Children’s, who is an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “Our study was the first to identify molecular signatures of cystic fibrosis from a blood test taken during a routine clinic visit, giving us a baseline. Greater understanding of these molecular signatures may lead to unique molecular markers that could help us intervene earlier to changes in a patient’s inflammatory response to airway infection or pancreatic function, allowing us to provide more focused treatment. It would be a huge improvement over the one-size-fits-all treatment approach we currently have for patients with cystic fibrosis.”
To identify baseline molecular signatures in cystic fibrosis, Dr. Levy’s lab obtained genomic information from patients’ blood samples using cutting-edge technologies such as Affymetric array and Illumina MiSeq. The team then merged this genomic information with each individual’s clinical history gathered from electronic medical records. They compared this snapshot of patient-specific data with healthy controls. Their study provides strong evidence for distinct molecular signatures in cystic fibrosis patients that correlate with clinical outcomes.
Cystic fibrosis is a progressive genetic disease that damages multiple organs, including the lungs and pancreas. Currently, the average predicted survival is 47 years. Although cystic fibrosis is caused by dysfunction of a single gene (CFTR) and treatment that targets CFTR mutations is available, the relationships between the abnormal gene product, development of inflammation and disease progression are not fully understood. This limits the ability to predict a patient’s clinical course, provide individualized treatment and rapidly monitor treatment response.
For example, it is not clear why patients with cystic fibrosis are susceptible to chronic lung infections, since they are considered to have a functional immune system.
“We are now trying to discover why patients with cystic fibrosis become infected so easily,” says Dr. Levy. “We are taking a closer look at the immune cells that make up many of the molecular signatures we found in cystic fibrosis.”
More study is needed before precision medicine for cystic fibrosis reaches the clinic.
“With more research, a blood test to gather genomic specifics of each patient’s disease might be available in the clinic within the next five years,” says Dr. Levy. “Precision medicine will revolutionize care for cystic fibrosis patients.”
The Latest on: Cystic fibrosis
via Google News
The Latest on: Cystic fibrosis
- No COVID risks for cystic fibrosis jockey who comes back with a bangon November 27, 2020 at 1:07 pm
Harry Coffey suffers from cystic fibrosis so it was hardly surprising when he put his whip, boots and saddles away when the worst of the coronavirus crisis deepened.
- Group Of Businesses Help Give Cystic Fibrosis Foundation’s Office A Makeoveron November 27, 2020 at 12:12 pm
WCCO reveals the makeover and shares why the collective group wants to continue to pay it forward. Step into the Cystic Fibrosis Foundation office in downtown Minneapolis and you know right where you ...
- EC OKs expanded use of Vertex's Symkevi with Kalydeco for children with cystic fibrosison November 27, 2020 at 6:38 am
The European Commission (EC) has granted approval of the label extension for' (NASDAQ:VRTX) Symkevi (tezacaftor/ivacaftor) with Kalydeco (ivacaftor), to include the treatment of cystic fibrosis ...
- Vertex: EU Approves SYMKEVI With KALYDECO For 6-11 Years Children With Cystic Fibrosison November 27, 2020 at 12:19 am
(RTTNews) - Vertex Pharmaceuticals Incorporated (VRTX) announced Friday that the European Commission has granted approval of the label extension for SYMKEVI (tezacaftor/ivacaftor) with KALYDECO ...
- Potential breakthrough for cystic fibrosis as Moscow scientists use gene-editing to correct part of mutation that causes diseaseon November 24, 2020 at 2:13 am
Scientists at Moscow's Bochkov Medical Genetic Research Center have successfully corrected a mutation of the CFTR gene, which causes cystic fibrosis. Using genetic editing, they replaced the parts of ...
- Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled antibiotic murepavadinon November 23, 2020 at 11:40 pm
Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in ...
- Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support ...on November 23, 2020 at 10:32 pm
Development program is currently jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI) until end of planned Phase Ia study ALLSCHWIL, Switzerland, Nov. 24, 2020 (GLOBE ...
- Understanding lung infections in patients with cystic fibrosison November 19, 2020 at 1:04 pm
Staphylococcus aureus (which includes MRSA) is the most prevalent organism isolated from the airways of children with cystic fibrosis (CF), and is treated using antibiotics, but its role in lung ...
- Simcoe–Grey MPP asks Prime Minister to speed up Cystic Fibrosis drug negotiationson November 19, 2020 at 9:42 am
Negotiations for gene modulating drugs that treat cystic fibrosis have dragged on longer than anticipated between the Federal government and Vertex ...
- Scots mum convinced she would die before Christmas makes miracle recovery thanks to new cystic fibrosis wonder drugon November 19, 2020 at 6:18 am
A MUM who was convinced she’d die of cystic fibrosis before Christmas says a miracle drug has transformed her life. Cheryl Dester, 33, is one of the first patients to be prescribed Kaftrio ...
via Bing News